| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
2 companies
Wahlstrom Mats serves as a Director at TLSI and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 4 buys and 9 sells. Those positions are worth an estimated $373K at current prices.
Historically, Wahlstrom Mats's trades have earned a middling insider score of 61/100 across 5 rated trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of -12.9%.
The biggest single holding is TLSI (~$373K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 75,727 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | TLSI Trisalus Life Sciences, Inc. | Director | Buy | 60,000 | $2.53 | $151,800.00 | +68.5% | +110.1% | - | |
| May 23, 2025 | CHRS Coherus Oncology, Inc. | Director | Sell | 99,988 | $0.74 | $73,881.13 | -100% | +49.5% | +112.9% | |
| Nov 22, 2024 | TLSI Trisalus Life Sciences, Inc. | Director, 10% Owner | Buy | 5,000 | $4.55 | $22,750.00 | +46.6% | +26.3% | +11.9% | |
| Nov 21, 2024 | TLSI Trisalus Life Sciences, Inc. | Director, 10% Owner | Buy | 10,727 | $4.39 | $47,056.68 | New | +29.1% | +14.4% | |
| Jun 17, 2020 | CHRS Coherus Oncology, Inc. | Director | Sell | 200,000 | $17.15 | $3,430,020.00 | -100% | - | - | |
| Mar 3, 2020 | CHRS Coherus Oncology, Inc. | Director | Sell | 118,066 | $20.12 | $2,375,409.16 | -37.1% | - | - | |
| Dec 8, 2016 | CHRS Coherus Oncology, Inc. | Director | Sell | 53,583 | $27.52 | $1,474,677.10 | -100% | - | - | |
| Aug 18, 2015 | CHRS Coherus Oncology, Inc. | Director | Sell | 6,373 | $33.50 | $213,508.25 | -1.1% | - | - | |
| Aug 17, 2015 | CHRS Coherus Oncology, Inc. | Director | Sell | 8,028 | $33.91 | $272,224.66 | -1.4% | - | - | |
| Aug 14, 2015 | CHRS Coherus Oncology, Inc. | Director | Sell | 116,554 | $34.24 | $3,990,377.71 | -16.4% | - | - |